AACR logo

More articles from MCT First Disclosures

SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance
Kristen Jensen-Pergakes, John Tatlock, Karen A. Maegley, Indrawan J. McAlpine, Michele McTigue, Tao Xie, Christopher P. Dillon, Yuli Wang, Shinji Yamazaki, Noah Spiegel, Manli Shi, Amy Nemeth, Natalie Miller, Eleanore Hendrickson, Hieu Lam, John Sherrill, Chi-Yeh Chung, Elizabeth A. McMillan, Shannon Karlicek Bryant, Prakash Palde, John Braganza, Alexei Brooun, Ya-Li Deng, Vesta Goshtasbi, Susan E. Kephart, Robert A. Kumpf, Wei Liu, Ryan L. Patman, Eugene Rui, Stephanie Scales, Michelle Tran-Dube, Fen Wang, Martin Wythes, Thomas A. Paul

Molecular Cancer Therapeutics Jan 2022, 21 (1) 3-15; DOI: 10.1158/1535-7163.MCT-21-0620
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
Daisuke Okajima, Satoru Yasuda, Takanori Maejima, Tsuyoshi Karibe, Ken Sakurai, Tetsuo Aida, Tadashi Toki, Junko Yamaguchi, Michiko Kitamura, Reiko Kamei, Tomomichi Fujitani, Tomoyo Honda, Tomoko Shibutani, Sumie Muramatsu, Takashi Nakada, Riki Goto, Shu Takahashi, Miki Yamaguchi, Hirofumi Hamada, Yutaka Noguchi, Masato Murakami, Yuki Abe, Toshinori Agatsuma

Molecular Cancer Therapeutics Dec 2021, 20 (12) 2329-2340; DOI: 10.1158/1535-7163.MCT-21-0206
Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
Dirk Brehmer, Lijs Beke, Tongfei Wu, Hillary J. Millar, Christopher Moy, Weimei Sun, Geert Mannens, Vineet Pande, An Boeckx, Erika van Heerde, Thomas Nys, Emmanuel M. Gustin, Bie Verbist, Longen Zhou, Yue Fan, Vipul Bhargava, Pegah Safabakhsh, Petra Vinken, Tinne Verhulst, Angelique Gilbert, Sumit Rai, Timothy A. Graubert, Friederike Pastore, Danilo Fiore, Junchen Gu, Amy Johnson, Ulrike Philippar, Barbara Morschhäuser, David Walker, Desiree De Lange, Vikki Keersmaekers, Marcel Viellevoye, Gaston Diels, Wim Schepens, Jan Willem Thuring, Lieven Meerpoel, Kathryn Packman, Matthew V. Lorenzi, Sylvie Laquerre

Molecular Cancer Therapeutics Dec 2021, 20 (12) 2317-2328; DOI: 10.1158/1535-7163.MCT-21-0367
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages
Bryan D. Smith, Michael D. Kaufman, Scott C. Wise, Yu Mi Ahn, Timothy M. Caldwell, Cynthia B. Leary, Wei-Ping Lu, Gege Tan, Lakshminarayana Vogeti, Subha Vogeti, Breelyn A. Wilky, Lara E. Davis, Maitreyi Sharma, Rodrigo Ruiz-Soto, Daniel L. Flynn

Molecular Cancer Therapeutics Nov 2021, 20 (11) 2098-2109; DOI: 10.1158/1535-7163.MCT-21-0361
A Novel Brain-Permeant Chemotherapeutic Agent for the Treatment of Brain Metastasis in Triple-Negative Breast Cancer
Jiaojiao Deng, Sophia B. Chernikova, Yuelong Wang, Mirna L. Rodriguez, Stephanie J. Andersen, Maxine C. Umeh-Garcia, Bryanna O. Godfrey, Saman S. Ahmadian, Wolf-Nicolas Fischer, Kerry J. Koller, Bernd Jandeleit, Gordon M. Ringold, Melanie Hayden Gephart

Molecular Cancer Therapeutics Nov 2021, 20 (11) 2110-2116; DOI: 10.1158/1535-7163.MCT-21-0140
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
Joanne M. Munck, Valerio Berdini, Luke Bevan, Jessica L. Brothwood, Juan Castro, Aurélie Courtin, Charlotte East, Roberta Ferraldeschi, Tom D. Heightman, Christopher J. Hindley, Justyna Kucia-Tran, John F. Lyons, Vanessa Martins, Sandra Muench, Christopher W. Murray, David Norton, Marc O'Reilly, Michael Reader, David C. Rees, Sharna J. Rich, Caroline J. Richardson, Alpesh D. Shah, Lukas Stanczuk, Neil T. Thompson, Nicola E. Wilsher, Alison J.-A. Woolford, Nicola G. Wallis

Molecular Cancer Therapeutics Oct 2021, 20 (10) 1757-1768; DOI: 10.1158/1535-7163.MCT-20-0909
SENTI-101, a Preparation of Mesenchymal Stromal Cells Engineered to Express IL12 and IL21, Induces Localized and Durable Antitumor Immunity in Preclinical Models of Peritoneal Solid Tumors
Alba Gonzalez-Junca, Frances D. Liu, Archana S. Nagaraja, Alyssa Mullenix, Chen-Ting Lee, Russell M. Gordley, Daniel O. Frimannsson, Ori Maller, Brian S. Garrison, Dharini Iyer, Anissa Benabbas, Tiffany A. Truong, Allison Quach, Mengxi Tian, Rowena Martinez, Rishi Savur, Alyssa Perry-McNamara, Denny Nguyen, Niran Almudhfar, Carmina Blanco, Christina Huynh, Asish Nand, Yu-An E. Lay, Ashita Magal, Sravani Mangalampalli, Philip J. Lee, Timothy K. Lu, Gary Lee

Molecular Cancer Therapeutics Sep 2021, 20 (9) 1508-1520; DOI: 10.1158/1535-7163.MCT-21-0030
TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations
Brion W. Murray, Dayong Zhai, Wei Deng, Xin Zhang, Jane Ung, Vivian Nguyen, Han Zhang, Maria Barrera, Ana Parra, Jessica Cowell, Dong J. Lee, Herve Aloysius, Evan Rogers

Molecular Cancer Therapeutics Sep 2021, 20 (9) 1499-1507; DOI: 10.1158/1535-7163.MCT-21-0221
Harnessing the hERG1/β1 Integrin Complex via a Novel Bispecific Single-chain Antibody: An Effective Strategy against Solid Cancers
Claudia Duranti, Jessica Iorio, Tiziano Lottini, Elena Lastraioli, Silvia Crescioli, Giacomo Bagni, Matteo Lulli, Chiara Capitani, Rayhana Bouazzi, Matteo Stefanini, Laura Carraresi, Luisa Iamele, Hugo De Jonge, Annarosa Arcangeli

Molecular Cancer Therapeutics Aug 2021, 20 (8) 1338-1349; DOI: 10.1158/1535-7163.MCT-20-1111
ASN004, A 5T4-targeting scFv-Fc Antibody–Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models
Roger A. Smith, David J. Zammit, Nitin K. Damle, Helen Usansky, Sanjeeva P. Reddy, Jun-Hsiang Lin, Mahesh Mistry, Niranjan S. Rao, Louis J. Denis, Sandeep Gupta

Molecular Cancer Therapeutics Aug 2021, 20 (8) 1327-1337; DOI: 10.1158/1535-7163.MCT-20-0565

Main menu

User menu

Search

More articles from MCT First Disclosures

Pages

Articles

Info for

About MCT